Boston Scientific’s Q3 2023 earnings report highlights significant growth in cardiology, with year-to-date U.S. growth at 27%, driven by successful product launches and innovation.
Edwards Lifesciences’ Q3 2024 results highlight a strong growth trajectory with a 9% increase in sales, driven by TAVR and TMTT segments, positioning the company for future success.
